Today: 9 June 2026
Browse Category

LSE:GOG 5 December 2025 - 8 December 2025

Wimbledon Station Incident Today: Man Dies as Emergency on Line Triggers Major Rail Chaos Between London and Surrey

Wimbledon Station Incident Today: Man Dies as Emergency on Line Triggers Major Rail Chaos Between London and Surrey

A man died after being found on the tracks near Wimbledon station Monday afternoon, prompting emergency services to close all rail lines in the area. National Rail warned of major disruption between London and Surrey, stranding thousands of commuters. South Western Railway and Thameslink services face cancellations, delays, and diversions, with disruption expected to last all day. British Transport Police have launched an investigation.
8 December 2025
··
TfL’s Moorgate Takeover Bid: Full List of Great Northern Stations That Could Join London Overground by 2027

TfL’s Moorgate Takeover Bid: Full List of Great Northern Stations That Could Join London Overground by 2027

Transport for London has submitted a formal proposal to take over Great Northern “inners” rail services from Moorgate, aiming for London Overground-style operations by late 2027, according to newly released documents. The plan includes doubling off-peak trains on the Welwyn Garden City and Hertford North branches and upgrading stations, using existing Class 717 trains. Approval would shift control from Govia Thameslink Railway.
5 December 2025

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop